Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

134.28 -0.32 (-0.24%)
Streaming Delayed Price Updated: 1:29 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma ADR

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Up Triple Digits As Second Quarter Kicks Off
The Dow Jones Industrial Average is up 146 points midday to kick off the second quarter, while the S&P 500 Index inches lower, and the Nasdaq Composite sits firmly in the red. 
Via Talk Markets
Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Nogin, Inc. (NASDAQ: NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 101% to $14.24 after climbing 50% on Friday. 
Via Benzinga
Why Ascendis Pharma Stock Is Plunging Today
A regulatory hiccup is weighing on the biopharma's shares today. 
Via The Motley Fool
Ascendis Pharma Flags Regulatory Delay In US For Its Hypoparathyroidism Candidate
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Crude Oil Jumps Over 6%; OncoSec Medical Shares Plummet
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. The Dow traded up 0.58% to 33,468.38 while the NASDAQ fell 0.96% to 12,104.67. The... 
Via Benzinga
Tesla, NIO And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug Application
The FDA decision prevents Ascendis from labeling and marketing the new drug application for TransCon PTH. ASND stock plunged 
Via Investor's Business Daily
ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND
From The Rosen Law Firm, P.A.
Via Business Wire
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Where Ascendis Pharma Stands With Analysts
Via Benzinga
What 9 Analyst Ratings Have To Say About Ascendis Pharma
Via Benzinga
Analyst Ratings for Ascendis Pharma
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Analyst Ratings for Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: 
Via Benzinga
6 Analysts Have This to Say About Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Ascendis Pharma
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Ascendis Pharma
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter: 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism
Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid... 
Via Benzinga
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
  Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.